
Please try another search
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Christopher M. Starr | 73 | 2022 | Independent Chairman |
Kim R. Tsuchimoto | 62 | 2022 | Independent Director |
Gregory Enns | - | 2022 | Member of Scientific Advisory Board |
David E. Housman | 78 | 2022 | Member of Scientific Advisory Board |
Brook G. Riggins | 59 | 2018 | CFO, Secretary & Director |
W. Hogan Mullally | 52 | 2018 | Independent Director |
Miriam Vos | - | 2022 | Member of Scientific Advisory Board |
Patrice P. Rioux | 74 | 2022 | Co-Founder, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review